"Regeneron has a series of new candidates, but President and Chief Scientific Officer George Yancopoulos said the company is waiting to see if cases rise again before testing the drugs in large trials, or seeing if the FDA will expedite authorization based on small trials."

Read More

"The drugmaker has started discussions with regulators to establish a development plan, Chief Scientific Officer George Yancopoulos said Monday in an online presentation to the JPMorgan Healthcare Conference. "

Read More

"Early tests suggest that the COVID-19 antibody treatment developed by Regeneron Pharmaceuticals Inc. loses effectiveness against the omicron variant of the coronavirus that causes COVID, but the full impact will only be known in the coming weeks after further testing, the company's president and chief scientific officer George Yancopoulos suggests it too is less effective against omicron. "

Read More